Lung Ambition Alliance

The World of Johan Cruyff joins Lung Ambition Alliance to drive improvements in diagnosis for lung cancer patients

Lung Ambition Alliance

The Lung Ambition Alliance is an initiative that brings together the commitment of scientific societies, patient associations and AstraZeneca to combine knowledge from different approaches with the common goal of doubling five-year survival in lung cancer by 2025.

The World of Johan Cruyff has announced that it has joined the Lung Ambition Alliance initiative to join forces to improve the survival of lung cancer patients. The work of the organization within the alliance is to contribute to the visibility and awareness of this disease. Around 29,000 new cases are diagnosed in Spain each year1 and it is one of the tumors with the highest incidence and the highest mortality rate (something that can be extrapolated worldwide1). These devastating figures are largely due to 57% of cases are diagnosed in advanced stages2. However, it is possible to change the future of these people. Early diagnosis will increase the percentage of patients in stage I (when the tumor is less than 3cm)3, which is crucial for survival, as more than 80% of these patients will still be alive at 5 years2.

Johan Cruyff died of lung cancer at the age 68 and this March 24 we remember that this was already 5 years ago. To honor his legacy in football and live, the World of Johan Cruyff (www.johancruyff.com) decided to join the Lung Ambition Alliance to play a role in its ambition to eliminate lung cancer as a cause of death.

“I think my father would be very proud that we have finally got all of us who have joined together to be part of the Lung Ambition Alliance working to improve the future of all lung cancer patients. Basically we want to improve quality and above all extend life expectancy.” Susila Cruyff

What is Lung Ambition Alliance?

This alliance was created with the commitment to double five-year survival in lung cancer by 2025. In our country, it has materialized by creating a committee made up of experts who have developed their professional careers on the front-line tackling lung cancer from different fields. In addition to The World of Johan Cruyff, also participate in the Lung Ambition Alliance Spain: the Spanish Society of Medical Oncology (SEOM), the Spanish Society of Radiation Oncology (SEOR), the Spanish Society of Pathological Anatomy-Spanish Division of the International Academy of Pathology (SEAP-IAP), Spanish Association of Lung Cancer Patients (AEACaP), the Spanish Cancer Patients Group (GEPAC), Spanish Society of Thoracic Surgery (SECT), Spanish Society of Pneumology and Thoracic Surgery (SEPAR), Spanish Lung Cancer Group (GECP), Spanish Society of Cardiothoracic Imaging (SEICAT), Spanish Society of Medical Radiology (SERAM), The Ricky Rubio Foundation and AstraZeneca.

A first pillar based on early diagnosis and the effectiveness, need and feasibility of implementing a screening system, fully compatible with primary prevention, has been addressed as the starting point of the project. In the coming months, this unprecedented alliance will address the other two pillars on which the initiative is based: innovative medicine development and quality patient care.

Susila Cruyff, will participate in the virtual event ‘The Time is Now: Together we build a future for lung cancer patients’ developed by the Lung Ambition Alliance Spain and which will take place today (February 17 ) at 17:00. During her intervention she will share his experience with the disease and will talk about the barriers that patients encounter. The event will also be attended by national and international healthcare professionals, patients and decision-makers, and aims to mobilize society and call for action to raise awareness of the need for early detection of the cancer with the highest mortality rate.

For more information, please check lungambitionalliance.com


About Lung Ambition Alliance

The Lung Ambition Alliance is a collaboration of diverse organizations united in a crusade to eliminate lung cancer as a cause of death. The Alliance’s goal is to accelerate progress and drive profound change for lung cancer patients by leveraging the expertise of each collaborating entity and prioritizing worthy projects that can contribute to its goal. The founding partners – International Association for the Study of Lung Cancer (IASLC), Guardant Health, Global Lung Cancer Coalition (GLCC) and AstraZeneca – will study and overcome barriers to screening and early diagnosis, to innovative drug development and quality care, and pursue an ambitious goal for the future of lung cancer that starts with a doubling of five-year survival by 2025.

References